Trial Profile
Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SUPERIOR
- 08 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 09 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.